Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Saturday, July 23, 2011
U.S. hepatitis B vaccination rate lagging
Study leader Dr. Rania Tohme of the Centers for Disease Control and Prevention in Atlanta analyzed hepatitis B immunization records of 4,075 healthcare students who matriculated at a university in the southeastern U.S. from January 2000 to January 2010.